Skip to content
a15a15a15

Drawing based on the description in the official product monograph. No photo yet.

“15 mg extended-release tablets are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with 'a15' on one side”

a15 pill

Pill with imprint a15 is purple, capsule, 8 mm and has been identified as Upadacitinib 15 mg. It is used for rheumatoid arthritis. It is supplied by Abbvie Corporation.

Sold in Canada

Upadacitinib 15 mg

Brand
Rinvoq
Imprint
a15
Strength
15 mg
Used for
Rheumatoid arthritis
Color
Purple
Shape
Capsule / oblong
Size
8 mm
Form
Tablet (extended-release)
Manufacturer
Abbvie Corporation
Drug class
Cancer medicine (kinase inhibitor)
Sold in
Canada
DIN
02495155

Source: Health Canada's Drug Product Database and the official product monograph. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Upadacitinib pills and guides

What is Upadacitinib used for?

Upadacitinib is used for rheumatoid arthritis.

Medicine type
Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label

Rheumatoid Arthritis

RINVOQ® is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.

  • Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.

Psoriatic Arthritis

RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.

  • Limitations of Use: RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.

Atopic Dermatitis

RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.

  • Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

Ulcerative Colitis

RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.

  • Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for UC, or with potent immunosuppressants such as azathioprine and cyclosporine.

Crohn’s Disease

RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.

  • Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for CD, or with potent immunosuppressants such as azathioprine and cyclosporine.

. 6 Ankylosing Spondylitis

RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.

  • Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.

. 7 Non-radiographic Axial Spondyloarthritis

RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy.

  • Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.

Polyarticular Juvenile Idiopathic Arthritis

RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an inadequate response or intolerance to one or more TNF blockers.

  • Limitations of Use: RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.

Giant Cell Arteritis

RINVOQ is indicated for the treatment of adults with giant cell arteritis.

  • Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.

From the FDA-approved label on DailyMed (published Jul 15, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows a15.
  • It is purple, capsule, 8 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold in Canada as Rinvoq by Abbvie Corporation.

In Canada: prescription only.

Ingredients

Active: Upadacitinib

Other pills with imprint A 15

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Upadacitinib pills